IWR1 Antibody

What is IWR-1 and what are its primary research applications?

IWR-1 is a small molecule that potently inhibits the Wnt/β-catenin signaling pathway by stabilizing the AXIN2 destruction complex, which enhances β-catenin degradation . The compound has shown significant potential in suppressing tumor metastasis, particularly in colorectal cancer research, by inhibiting epithelial-mesenchymal transition (EMT) and decreasing survivin expression . IWR-1 functions by blocking Axin protein turnover, which leads to enhanced β-catenin destruction and subsequent inhibition of downstream target gene expression .

What structural variants of IWR-1 exist and how do they differ in efficacy?

IWR-1 exists in two diastereomeric forms: IWR-1-endo and IWR-1-exo . The "endo" form demonstrates higher activity against the Wnt/β-catenin pathway compared to the "exo" form . Additionally, a fragment of IWR (IWR-frag) lacking the quinoline group has been identified as incapable of inhibiting Wnt/β-catenin pathway activity, highlighting the importance of the quinoline moiety for biological activity . These structural differences have significant implications for experimental design, as researchers must select the appropriate form for their specific applications.

How does IWR-1 affect Wnt/β-catenin signaling in colorectal cancer models?

IWR-1 inhibits Wnt/β-catenin signaling by enhancing the β-catenin destruction complex through stabilizing Axin . In colorectal cancer models, this mechanism leads to:

• Decreased β-catenin accumulation and nuclear translocation

• Reduced expression of Wnt target genes, including survivin

• Inhibition of cell proliferation in a dose- and time-dependent manner

• Reversal of EMT, even in the presence of TNF-α-induced stimulation

This mechanism is particularly relevant in colorectal cancer where aberrant activation of Wnt/β-catenin signaling is frequently observed and considered a major determinant of pathogenesis .

What is the relationship between IWR-1, survivin expression, and EMT in cancer progression?

IWR-1 provides EMT reversal effects primarily by directly suppressing survivin expression, as evidenced by multiple experimental approaches:

• IWR-1 could not completely inhibit EMT in survivin-overexpressing HCT116 cells

• EMT reversal effects of IWR-1 were more pronounced in survivin-suppressed cells

• Survivin promoter assays identified a 179-bp DNA element from −189 to −11 bp as playing a major role in IWR-1-mediated inhibition of survivin promoter activity

These findings suggest that survivin is a critical downstream mediator of IWR-1's effects on EMT and cancer cell invasion.

What are the optimal experimental conditions for studying IWR-1 effects in cell culture?

Based on established protocols, the following conditions are recommended:

• Concentration range: 5–50 μM IWR-1 for dose-dependent studies

• Treatment duration: 24-48 hours for time-dependent effects

• Cell lines: HCT116 (without APC mutation) and HT29, SW480, SW620 (with APC mutation) are well-characterized models

• Controls: Include TNF-α (10 ng/ml) as a positive control for EMT induction

• EMT markers to monitor: E-cadherin (epithelial), N-cadherin, Vimentin, and Snail (mesenchymal)

For EMT studies, both protein (Western blot, immunofluorescence) and mRNA (RT-qPCR) analyses should be performed to comprehensively assess the effects of IWR-1.

How can researchers accurately quantify IWR-1 in biological samples?

LC-MS/MS methodology has been validated for IWR-1-endo determination in biological matrices with the following parameters:

• Sample preparation: IWR-1-endo can be prepared in methanol (0.001 mg/mL)

• Ionization mode: Positive ion mode is preferred as IWR-1-endo is easily protonated

• Detection: Molecular ion peak [M+H]+

• Internal standard: Dabrafenib has been used successfully

• Validation parameters: For murine plasma, relative error ranges from −0.86% to 9.26% with RSD below 10.10%; for microdialysate samples, relative error ranges from −8.86% to 0.21% with RSD below 7.31%

This methodology provides reliable and reproducible quantification of IWR-1-endo in experimental samples.

How effective is IWR-1 in inhibiting cell migration and invasion in colorectal cancer?

IWR-1 demonstrates significant inhibition of colorectal cancer cell migration and invasion across multiple experimental models:

• In Transwell invasion assays, IWR-1 significantly inhibited TNF-α-induced cell invasion

• In wound healing assays, IWR-1 significantly reduced cell migration

• IWR-1 significantly reduced MMP2 and MMP9 activities, which are critical for extracellular matrix degradation during invasion

• These effects were consistent across different cell lines (HCT116 and HT29)

The inhibitory effects on migration and invasion mechanisms suggest that IWR-1 has potential as an anti-metastatic agent in colorectal cancer.

How does IWR-1 perform in ex vivo tissue models compared to cell lines?

IWR-1 shows consistent effects in both in vitro cell lines and ex vivo patient-derived tissue models:

• In ex vivo models using CRC tissues cultured with or without TNF-α and/or IWR-1, the compound significantly decreased protein expressions of β-catenin and survivin

• IWR-1 inhibited EMT in patient-derived tissues even in the presence of TNF-α-induced EMT stimulation

• RT-qPCR and immunohistochemical stains confirmed that IWR-1 increased E-cadherin and decreased survivin and Snail at both mRNA and protein levels

This consistency across different models strengthens the translational potential of IWR-1 as a therapeutic agent.

How does genetic background affect IWR-1 efficacy in different cancer cell lines?

IWR-1 has demonstrated consistent EMT inhibition across colorectal cancer cell lines with different genetic backgrounds:

• Equally effective in cell lines with APC mutations (HT29, SW480, and SW620) and without APC mutations (HCT116)

• Blocks β-catenin accumulation induced by loss of APC tumor suppressor

• Inhibits aberrant Wnt/β-catenin pathway activity in colorectal cancer regardless of specific mutation profiles

This broad efficacy across different genetic backgrounds suggests IWR-1 may have wide applicability in heterogeneous patient populations.

What is the relationship between IWR-1 and the PI3K/Akt signaling pathway?

IWR-1 effectively inhibits Akt expression in a dose- and time-dependent manner, but its mechanism appears to be indirect:

• When Akt was overexpressed by transfection with pcDNA3.1Myr-Akt, IWR-1 still exerted EMT reversal potential

• This suggests IWR-1 acts on downstream molecules of Akt signaling rather than directly on Akt itself

• Survivin is a downstream molecule of Akt signaling that promotes EMT, and IWR-1's effects appear to be mediated through survivin suppression

Understanding this relationship helps elucidate the broader signaling network affected by IWR-1 treatment.

How can researchers validate the specificity of IWR-1 effects in their experimental system?

To validate IWR-1 specificity, researchers should consider the following approaches:

• Use diastereomeric controls: Compare IWR-1-endo with the less active IWR-1-exo form

• Use fragment controls: Include IWR-frag (lacking the quinoline group) as a negative control

• Perform genetic manipulations: Test IWR-1 effects in cells with:

  • Survivin overexpression (using pcDNA-survivin)

  • Survivin suppression (using si-Survivin)

• Examine multiple downstream targets: Assess β-catenin, EMT markers, and MMP activities to confirm mechanism of action

These validation steps help distinguish specific IWR-1 effects from potential off-target actions.

What are the potential limitations of IWR-1 in research applications?

Researchers should be aware of several limitations when working with IWR-1:

• Diastereomeric specificity: The efficacy is highly dependent on using the correct isomer (endo vs. exo)

• Survivin-dependent mechanisms: In systems where survivin is constitutively overexpressed, IWR-1 may show reduced efficacy

• Concentration-dependent effects: At high concentrations, non-specific effects may occur

• Limited in vivo data: While ex vivo data is promising, more comprehensive in vivo studies are needed to fully understand pharmacokinetics and efficacy

Addressing these limitations through careful experimental design is essential for obtaining reliable results.